Currently, the available data on the use of PSMA PET in these two subtypes is limited, making it necessary to develop specific trials to better understand the differences in PSMA expressions both in the primary tumor and in metastases, as well as its potential clinical impact in each of these neoplasms. This evidence concerns the gene FOLH1 and neoplasm.